Insider Selling: Genelux (NASDAQ:GNLX) Director Sells 12,000 Shares

Posted by George Bondi on Jul 2nd, 2026

Genelux Corporation (NASDAQ:GNLX – Get Free Report) Director John Smither sold 12,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total value of $34,920.00. Following the transaction, the director owned 91,403 shares of the company’s stock, valued at approximately $265,982.73. This represents a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Genelux Trading Up 3.1%

GNLX traded up $0.09 on Thursday, hitting $2.99. The company had a trading volume of 195,980 shares, compared to its average volume of 220,434. The firm has a market cap of $134.07 million, a P/E ratio of -3.52 and a beta of 0.58. Genelux Corporation has a 1 year low of $2.29 and a 1 year high of $8.53. The company’s fifty day moving average price is $2.88 and its 200 day moving average price is $2.94.

Genelux (NASDAQ:GNLX – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, analysts predict that Genelux Corporation will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On Genelux

Hedge funds have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. acquired a new position in shares of Genelux in the fourth quarter worth $48,000. Squarepoint Ops LLC purchased a new position in Genelux in the fourth quarter valued at $52,000. Raymond James Financial Inc. boosted its holdings in Genelux by 22.6% in the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after purchasing an additional 5,333 shares during the period. Marshall Wace LLP acquired a new position in Genelux during the 2nd quarter worth $92,000. Finally, Balyasny Asset Management L.P. purchased a new stake in Genelux during the 4th quarter worth about $94,000. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GNLX. Benchmark cut their target price on Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a research report on Friday, March 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research note on Tuesday, April 21st. Finally, Wall Street Zen downgraded Genelux from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

View Our Latest Stock Analysis on Genelux

About Genelux

(Get Free Report)

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.